Additionally, we performed a detailed examination of the clinical trials that utilized a combination of CDK4/6is and immunotherapy for cancer treatment, discussing the problems with the combined treatment strategy and the associations with the “duality” of CDK4/6is, which have not been found in previous reviews. This evidence concerns the gene CDK4 and cancer.